Literature DB >> 26207052

Minimizing Hypoglycemia in Diabetes.

.   

Abstract

Hypoglycemia caused by treatment with a sulfonylurea, a glinide, or insulin coupled with compromised defenses against the resulting falling plasma glucose concentrations is a problem for many people with diabetes. It is often recurrent, causes significant morbidity and occasional mortality, limits maintenance of euglycemia, and impairs physiological and behavioral defenses against subsequent hypoglycemia. Minimizing hypoglycemia includes acknowledging the problem; considering each risk factor; and applying the principles of intensive glycemic therapy, including drug selection and selective application of diabetes treatment technologies. For diabetes health-care providers treating most people with diabetes who are at risk for or are suffering from iatrogenic hypoglycemia, these principles include selecting appropriate individualized glycemic goals and providing structured patient education to reduce the incidence of hypoglycemia. This is typically combined with short-term scrupulous avoidance of hypoglycemia, which often will reverse impaired awareness of hypoglycemia. Clearly, the risk of hypoglycemia is modifiable.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26207052     DOI: 10.2337/dc15-0279

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  52 in total

1.  Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care.

Authors:  Melanie J Davies; Sudesna Chatterjee
Journal:  Nat Rev Endocrinol       Date:  2017-04-07       Impact factor: 43.330

2.  Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with naltrexone.

Authors:  Sarita Naik; Renata Belfort-DeAguiar; Anne-Sophie Sejling; Barbara Szepietowska; Robert S Sherwin
Journal:  Diabetes Obes Metab       Date:  2017-02-17       Impact factor: 6.577

3.  Diabetes: Predicting severe hypoglycaemia - a step forward.

Authors:  Francesco Zaccardi; Kamlesh Khunti
Journal:  Nat Rev Endocrinol       Date:  2017-10-23       Impact factor: 43.330

4.  Analyzing the Potential of Advanced Insulin Dosing Strategies in Patients With Type 2 Diabetes: Results From a Hybrid In Silico Study.

Authors:  Florian Reiterer; Matthias Reiter; Luigi Del Re; Merete Bechmann Christensen; Kirsten Nørgaard
Journal:  J Diabetes Sci Technol       Date:  2018-04-21

5.  GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia.

Authors:  Nina Xiaoyan Li; Stacey Brown; Tim Kowalski; Margaret Wu; Liming Yang; Ge Dai; Aleksandr Petrov; Yuyan Ding; Tamara Dlugos; Harold B Wood; Liangsu Wang; Mark Erion; Robert Sherwin; David E Kelley
Journal:  Diabetes       Date:  2018-04-18       Impact factor: 9.461

6.  Outcomes of people with severe hypoglycaemia requiring prehospital emergency medical services management: a prospective study.

Authors:  Melanie Villani; Arul Earnest; Karen Smith; Dimitra Giannopoulos; Georgia Soldatos; Barbora de Courten; Sophia Zoungas
Journal:  Diabetologia       Date:  2019-07-15       Impact factor: 10.122

7.  Medication Knowledge and Adherence in Type 2 Diabetes Mellitus Patients in Brunei Darussalam: A Pioneer Study in Brunei Darussalam.

Authors:  Najwa Hazwani Muhammad Haskani; Hui Poh Goh; Daniel Vui Teck Wee; Andi Hermansyah; Khang Wen Goh; Long Chiau Ming
Journal:  Int J Environ Res Public Health       Date:  2022-06-18       Impact factor: 4.614

Review 8.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

9.  Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.

Authors:  Johannes Pöhlmann; Beth D Mitchell; Sanjay Bajpai; Beatrice Osumili; William J Valentine
Journal:  J Diabetes Sci Technol       Date:  2019-01-30

10.  Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.

Authors:  Ulrik Pedersen-Bjergaard; Rikke M Agesen; Julie M B Brøsen; Amra C Alibegovic; Henrik U Andersen; Henning Beck-Nielsen; Peter Gustenhoff; Troels K Hansen; Christoffer Hedetoft; Tonny J Jensen; Claus B Juhl; Andreas K Jensen; Susanne S Lerche; Kirsten Nørgaard; Hans-Henrik Parving; Anne L Sørensen; Lise Tarnow; Birger Thorsteinsson
Journal:  Diabetes Obes Metab       Date:  2021-11-02       Impact factor: 6.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.